Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities (FPI)

July 28, 2025 updated by: Sannisha K Dale, University of Miami

Five Point Initiative: A Cluster Randomized Trial of a Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities

The purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Florida
      • Miami, Florida, United States, 33136
        • Recruiting
        • University of Miami
        • Contact:
        • Principal Investigator:
          • Sannisha Dale, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Any individual present during the community events at the "five points" (barbershop, hair/beauty salon store or salon, corner store/grocery/neighborhood restaurant, laundromats, car service provider [e.g. gas station, mechanic, car wash]) in predominantly Black communities in Miami where HIV prevalence is high.
  • Pre- and Post-assessment: Individuals are only eligible to complete the survey one time during the Pre-Intervention and during the Post-Intervention phases.
  • Intervention: Individuals are only eligible to participate in the Intervention phase of this study once every 6 months.

Exclusion Criteria:

  • Individuals who are unable to completely and fully understand the informed (verbal) consent process and the study procedures.
  • Individuals who have previously completed the survey during the Pre-Intervention and Post-Intervention phases.
  • Individuals who have participated in the Intervention phase of this study within less than 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FPI Group
Participants in this group will receive the FPI intervention at any FPI coordinated outreach event (4-5 hours) during a 21 month period
The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
No Intervention: Pre-intervention Assessment Group
We will conduct pre-assessment events (4-5 hours) during 1.5 months in each zip code (prior to the introduction of the FPI intervention) to capture information from residents /participants via survey.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in number of residents with recent HIV testing
Time Frame: Up to 23 months
Will be reported as proportion of residents with recent (within 12 months) HIV testing as measured by Five Point Initiative - Community Survey
Up to 23 months
Change in number of residents with PrEP prescription
Time Frame: Up to 23 months
Will be reported as proportion of residents with PrEP prescription as measured by Five Point Initiative - Community Survey
Up to 23 months
Change in PrEP knowledge as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
Will be reported as the proportion of residents that indicated 'Yes' on the survey.
Baseline and up to 23 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in condom use as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
Will be reported as the proportion of residents that indicated 'No' on the survey
Baseline and up to 23 months
Change in condom access as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
Will be reported as the proportion of residents that indicated 'Yes' on the survey
Baseline and up to 23 months
Proportion of residents with recent HIV testing by health organizations
Time Frame: Up to 23 months
Proportion of residents with recent (within 12 months) HIV testing by each of the participating health organizations.
Up to 23 months
Number of residents with PrEP prescription by health organizations
Time Frame: Up to 23 months
Number of residents with PrEP prescription by each of the participating health organizations.
Up to 23 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sannisha Dale, PhD, University of Miami

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2024

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

September 25, 2023

First Submitted That Met QC Criteria

September 25, 2023

First Posted (Actual)

October 2, 2023

Study Record Updates

Last Update Posted (Actual)

July 29, 2025

Last Update Submitted That Met QC Criteria

July 28, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 20230484
  • 1R01MH134269-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hiv

Clinical Trials on FPI

Subscribe